Ten Years of Leadership in Immunotherapy
The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.
Lieping Chen, PhD, wins prestigious 2017 Warren Alpert Prize
Lieping Chen, Ph.D., co-director of the Cancer Immunology Program at Yale Cancer Center and United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology and of medicine at Yale School of Medicine, has been presented with the 2017 Warren Alpert Foundation Prize for transformative discoveries in the field of cancer immunology.
Lieping Chen among five scientists recognized for discoveries in cancer immunology
Lieping Chen, Ph.D., the United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology, and of medicine, is one of five scientists to receive the 2017 Warren Alpert Foundation Prize.
Innovation to Impact: Dr. Lieping Chen and NextCure
Dr. Lieping Chen is a pioneer in the field of immuno-oncology and his discoveries have led to life-saving drugs for cancer patients. Now, with the support of the Yale Office of Cooperative Research, Dr. Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.
Central Nervous System Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear. Now, Yale researchers have identified a mechanism that offers this new insight into this protective effect. The findings were described in the April 8 journal of Science Advances.
New Germantown biotech nets $67 million from investors
New Germantown biotech nets $67 million from investors, including Eli Lilly and Pfizer to fund research and development in Dr. Lieping Chen’s laboratory. Immuno-oncology has attracted growing notice over the past few years, but only a handful of drugs in the nascent field have been approved for broad public use. Two of those drugs leading the charge — Keytruda and Opdivo — target the PD-1/PD-L1 pathway that Chen is credited with innovating. Keytruda, manufactured by Merck, made headlines last year when former president Jimmy Carter said he was using it to treat cancerous tumors in his brain and liver. Carter said in December that he is cancer-free.Source: The Washington Post
Yale Cancer Center receives $11 million from National Cancer Institute for lung cancer research
Armed with an $11 million grant from the National Cancer Institute (NCI), Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world’s most prevalent and lethal forms of cancer.
INSIGHT-Pfizer, Bristol revive cancer drugs that rev up immune system
Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system's attack.Source: Reuters
FDA approves new immunotherapy drug used at Yale Cancer Center for metastatic lung cancer
The FDA has approved an immunotherapy drug for patients with previously-treated advanced squamous non-small cell lung cancer (NSCLC). Nivolumab, used in multiple clinical trials at Yale Cancer Center for metastatic lung cancer and melanoma, is the only FDA-approved monotherapy in 15 years to demonstrate proven superior overall survival compared to standard of care for this type of cancer.
Tackling cancer with a new paradigm
In the 1980s, immunotherapy researcher Lieping Chen, M.D., Ph.D., embraced the career goal of curing one cancer. That lofty-seeming goal is beginning to look more modest today. Recent clinical trials have shown that one cancer after another is vulnerable to immune modulation therapy, a cancer-fighting strategy Chen pioneered that for years was considered marginal.
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute.Source: Cancer Research Institute
United Technologies Endows Yale Cancer Center Professorship for Research
The fight against cancer in Connecticut is getting a major boost from United Technologies Corp. (NYSE: UTX), which has donated $3 million to establish a new endowed professorship at Yale Cancer Center (YCC) in New Haven, Conn.
Dr. Lieping Chen is named to the inaugural United Technologies Corporation endowed post
Dr. Lieping Chen, newly appointed as the United Technologies Corporation Professor in Cancer Research, focuses his research on developing new treatment options for cancer. His laboratory discovered the B7-H1/PD-1 immune inhibitory pathway and established the principle of cancer therapy by blocking this pathway.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.